-
Mashup Score: 2Precision Immuno-Oncology in NSCLC through Gender Equity Lenses - 20 day(s) ago
Precision immuno-oncology involves the development of personalized cancer treatments that are influenced by the unique nature of an individual’s DNA, immune cells, and their tumor’s molecular characterization. Biological sex influences immunity; females typically mount stronger innate and adaptive immune responses than males. Though more research is warranted, we continue to observe an enhanced benefit for females with lung cancer when treated with combination chemoimmunotherapy in contrast to the preferred approach of utilizing immunotherapy alone in men. Despite the observed sex differences in response to treatments, women remain underrepresented in oncology clinical trials, largely as a result of gender-biased misconceptions. Such exclusion has resulted in the development of less efficacious treatment guidelines and clinical recommendations and has created a knowledge gap in regard to immunotherapy-related survivorship issues such as fertility. To develop a more precise approach to
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Home - Young Lung Cancer Initiative - 21 day(s) ago
“We strive to positively impact early diagnoses, treatments, research, and survival for YOUNG adults diagnosed with LUNG CANCER” WHY YOUNG LUNG CANCER? Genetics are more likely to contribute to lung cancer for people who are young (under 50), have never smoked, or female. Lung cancer in individuals who have never smoked is estimated to be…
Source: ylci.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Lung Cancer Considered | IASLC - 1 month(s) ago
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Sara: Nurse Practitioner, Mother, & Never-Smoker, Diagnosed with RET+ Lung Cancer in 2010 - 1 month(s) ago
Sara was diagnosed with lung cancer in 2010. “I’ve had it all – chemo, radiation, immunotherapy, surgery – & since 2017 a targeted therapy known at the time …
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1RETpositive | Empowering Patients and Driving Research - 1 month(s) ago
RETpositive is a patient-driven 501(c)(3) nonprofit that aims to improve the quality of life and life expectancy of RET-positive cancer patients by raising awareness, providing community support and advocacy, and funding medical research for RET-driven cancer.
Source: www.retpositive.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Same BUT Different: Lung Cancer with Gender Equity Lenses - 2 month(s) ago
Speaker: Narjust Florez, MDModerator: Marquita Lewis Thames, PhD
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Same BUT Different: Lung Cancer with Gender Equity Lenses - 2 month(s) ago
Speaker: Narjust Florez, MDModerator: Marquita Lewis Thames, PhD
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Lung Cancer Considered | IASLC - 2 month(s) ago
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24Lung Cancer Living Room - GO2 for Lung Cancer - 2 month(s) ago
Every month our Lung Cancer Living Room sessions bring hope home to patients and their families. Learn about the multiple monthly events!
Source: go2.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64Lung Cancer in Women: The Past, Present, and Future - 2 month(s) ago
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
RT @Florez_Lab: 🚨No paywall‼️ 🗞️Read #openaccess article now👇👇👇: 🔗: https://t.co/vXcofWKL4y https://t.co/g6RAk3oTLt